안티에이징 의약품 시장 분석 및 예측(-2035년) : 유형, 제품, 용도, 제형, 최종사용자, 스테이지, 성별

The global Anti Aging Drugs Market is projected to grow from $55.9 billion in 2025 to $102.4 billion by 2035, at a compound annual growth rate (CAGR) of 6.4%. The expanding aging population is a major driver for the anti-aging drugs market, as rising life expectancy and a growing elderly demographic increase demand for preventive and therapeutic interventions. According to global estimates, the population aged 60 and above is expected to reach 2.1 billion by 2050, significantly expanding the target patient base. This trend is further supported by increasing prevalence of chronic diseases, encouraging research into senolytics and metformin-based therapies. In countries like India, the elderly population is projected to reach 20% by 2050, while global life expectancy is expected to rise from 73.3 years in 2024 to 77.4 years by 2054, creating substantial growth opportunities.

By Type, the market is segmented into Hormonal Therapy, Antioxidants, Enzymes, Stem Cell, and Others, with hormonal therapy accounting for the largest share of 31.4% in 2025. This dominance is driven by its proven effectiveness in addressing age-related hormonal decline and improving overall health outcomes. Clinical evidence supports its growing adoption; for instance, a study by UK Biobank found that individuals aged over 45 using hormonal therapy for 4 to 8 years showed reduced aging discrepancy. Additionally, increasing adoption among postmenopausal women is notable, as a 2025 JAMA Network Open study reported that hormonal therapy can modestly reduce biological age.

By Form, the market is segmented into Creams & Lotions, Serums, Tablets & Capsules, Gels, and Others, with creams & lotions accounting for the largest share of 35.4% in 2024 due to their visible firming, contouring, and hydration benefits. Their ease of use and effectiveness in daily skincare routines continue to drive widespread adoption. Meanwhile, advanced serums are gaining strong traction, accounting for the third-largest share of 19.6% in 2025, as they offer targeted anti-aging solutions such as wrinkle reduction and skin repair. Recent developments, including product launches in September 2025, highlight increasing innovation and growing consumer preference for specialized formulations.

Geographical Overview

North America dominates the anti-aging drugs market, accounting for a 33.8% share in 2025, driven by shifting consumer preferences toward scientifically validated formulations such as antioxidants, peptides, and NAD+-based therapies. Growing interest in minimally invasive interventions targeting biological aging is further supporting market expansion. Strong clinical research activity, rising biotech R&D investments, and advancements in senolytics and cellular repair are reinforcing long-term growth across both prescription and OTC segments. In April 2024, Life Biosciences acquired Senolytic Therapeutics for USD 450 million, strengthening its pipeline of age-related therapeutic candidates.

Asia Pacific is the fastest-growing region in the anti-aging drugs market, registering a CAGR of 8.2% during the forecast period. Growth is driven by rapidly aging populations in countries such as Japan, China, and South Korea, along with increasing healthcare expenditure and rising awareness of longevity-focused therapies. Japan, in particular, is advancing the market through strong government support and targeted research funding for age-related innovations. In 2025, Chugai Pharmaceutical partnered with Gero to combine AI-driven aging target discovery with antibody engineering, accelerating the development of next-generation anti-aging therapeutics.

Key Trends and Drivers

Longevity-Driven Pharmaceutical Breakthroughs Shaping the Anti-Aging Drugs

Longevity-driven pharmaceutical breakthroughs are transforming the anti-aging drugs market, with AI-enabled discovery significantly accelerating clinical development. Advanced technologies such as multi-omics analysis are enabling the identification of dual-purpose targets for aging and related diseases, improving precision and reducing development timelines. This approach is reshaping how therapies are designed and validated. At the same time, repurposing existing FDA-approved drugs is emerging as a cost-effective strategy to target aging mechanisms, particularly cellular senescence. Recent developments highlight increasing investment and confidence in small-molecule therapies, as companies focus on scalable, faster-to-market solutions for addressing age-related conditions and extending healthy lifespan.

AI-Driven Drug Discovery Accelerating Anti-Aging Therapeutic Development

AI-driven drug discovery is significantly accelerating the development of anti-aging therapeutics by enabling efficient analysis of large-scale biological datasets. Advanced platforms can screen millions of samples to identify potential age-modifying interventions, substantially reducing research timelines and costs. This data-driven approach enhances precision in target identification and supports faster pipeline progression. Additionally, machine learning is improving the identification of safe and effective senolytics by screening thousands of compounds to selectively eliminate harmful aging cells. These advancements are increasing confidence in anti-aging drug development, enabling more efficient discovery processes and supporting the emergence of targeted, scalable longevity therapies.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Strategic Recommendations
• 1.5 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Form
• 2.3 Key Market Highlights by Stage
• 2.4 Key Market Highlights by Product
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by Gender

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Technologies Landscape
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTLE Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Hormonal Therapy
  • 4.1.2 Antioxidants
  • 4.1.3 Enzymes
  • 4.1.4 Stem Cell
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Form (2020-2035)
  • 4.2.1 Creams & Lotions
  • 4.2.2 Serums
  • 4.2.3 Tablets & Capsules
  • 4.2.4 Gels
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Stage (2020-2035)
  • 4.3.1 Prevention
  • 4.3.2 Early Intervention
  • 4.3.3 Chronic Management
  • 4.3.4 Supportive Care
  • 4.3.5 Palliative Care
• 4.4 Market Size & Forecast by Product (2020-2035)
  • 4.4.1 Topical
  • 4.4.2 Oral
  • 4.4.3 Injectable
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals & Clinics
  • 4.5.2 Home Care
  • 4.5.3 Wellness Centers
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Skin Care
  • 4.6.2 Hair Care
  • 4.6.3 Bone & Joint Health
  • 4.6.4 Immune Health
  • 4.6.5 Age-related Disorders
  • 4.6.6 Others
• 4.7 Market Size & Forecast by Gender (2020-2035)
  • 4.7.1 Female
  • 4.7.2 Male

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Form
    • 5.2.1.3 Stage
    • 5.2.1.4 Product
    • 5.2.1.5 End User
    • 5.2.1.6 Application
    • 5.2.1.7 Gender
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Form
    • 5.2.2.3 Stage
    • 5.2.2.4 Product
    • 5.2.2.5 End User
    • 5.2.2.6 Application
    • 5.2.2.7 Gender
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Form
    • 5.2.3.3 Stage
    • 5.2.3.4 Product
    • 5.2.3.5 End User
    • 5.2.3.6 Application
    • 5.2.3.7 Gender
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Form
    • 5.3.1.3 Stage
    • 5.3.1.4 Product
    • 5.3.1.5 End User
    • 5.3.1.6 Application
    • 5.3.1.7 Gender
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Form
    • 5.3.2.3 Stage
    • 5.3.2.4 Product
    • 5.3.2.5 End User
    • 5.3.2.6 Application
    • 5.3.2.7 Gender
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Form
    • 5.3.3.3 Stage
    • 5.3.3.4 Product
    • 5.3.3.5 End User
    • 5.3.3.6 Application
    • 5.3.3.7 Gender
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Form
    • 5.4.1.3 Stage
    • 5.4.1.4 Product
    • 5.4.1.5 End User
    • 5.4.1.6 Application
    • 5.4.1.7 Gender
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Form
    • 5.4.2.3 Stage
    • 5.4.2.4 Product
    • 5.4.2.5 End User
    • 5.4.2.6 Application
    • 5.4.2.7 Gender
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Form
    • 5.4.3.3 Stage
    • 5.4.3.4 Product
    • 5.4.3.5 End User
    • 5.4.3.6 Application
    • 5.4.3.7 Gender
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Form
    • 5.4.4.3 Stage
    • 5.4.4.4 Product
    • 5.4.4.5 End User
    • 5.4.4.6 Application
    • 5.4.4.7 Gender
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Form
    • 5.4.5.3 Stage
    • 5.4.5.4 Product
    • 5.4.5.5 End User
    • 5.4.5.6 Application
    • 5.4.5.7 Gender
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Form
    • 5.4.6.3 Stage
    • 5.4.6.4 Product
    • 5.4.6.5 End User
    • 5.4.6.6 Application
    • 5.4.6.7 Gender
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Form
    • 5.4.7.3 Stage
    • 5.4.7.4 Product
    • 5.4.7.5 End User
    • 5.4.7.6 Application
    • 5.4.7.7 Gender
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Form
    • 5.5.1.3 Stage
    • 5.5.1.4 Product
    • 5.5.1.5 End User
    • 5.5.1.6 Application
    • 5.5.1.7 Gender
  • 5.5.2 United Kingdom
    • 5.5.2.1 Type
    • 5.5.2.2 Form
    • 5.5.2.3 Stage
    • 5.5.2.4 Product
    • 5.5.2.5 End User
    • 5.5.2.6 Application
    • 5.5.2.7 Gender
  • 5.5.3 France
    • 5.5.3.1 Type
    • 5.5.3.2 Form
    • 5.5.3.3 Stage
    • 5.5.3.4 Product
    • 5.5.3.5 End User
    • 5.5.3.6 Application
    • 5.5.3.7 Gender
  • 5.5.4 Italy
    • 5.5.4.1 Type
    • 5.5.4.2 Form
    • 5.5.4.3 Stage
    • 5.5.4.4 Product
    • 5.5.4.5 End User
    • 5.5.4.6 Application
    • 5.5.4.7 Gender
  • 5.5.5 Spain
    • 5.5.5.1 Type
    • 5.5.5.2 Form
    • 5.5.5.3 Stage
    • 5.5.5.4 Product
    • 5.5.5.5 End User
    • 5.5.5.6 Application
    • 5.5.5.7 Gender
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Form
    • 5.5.6.3 Stage
    • 5.5.6.4 Product
    • 5.5.6.5 End User
    • 5.5.6.6 Application
    • 5.5.6.7 Gender
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Form
    • 5.6.1.3 Stage
    • 5.6.1.4 Product
    • 5.6.1.5 End User
    • 5.6.1.6 Application
    • 5.6.1.7 Gender
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Form
    • 5.6.2.3 Stage
    • 5.6.2.4 Product
    • 5.6.2.5 End User
    • 5.6.2.6 Application
    • 5.6.2.7 Gender
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Form
    • 5.6.3.3 Stage
    • 5.6.3.4 Product
    • 5.6.3.5 End User
    • 5.6.3.6 Application
    • 5.6.3.7 Gender
  • 5.6.4 Rest of MEA
    • 5.6.4.1 Type
    • 5.6.4.2 Form
    • 5.6.4.3 Stage
    • 5.6.4.4 Product
    • 5.6.4.5 End User
    • 5.6.4.6 Application
    • 5.6.4.7 Gender

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Merz Pharma
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Procter & Gamble
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Nu Skin
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 BIOTIME Inc (Lineage Cell Therapeutic)
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Elysium Health Inc.
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Dermafix
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 L'OrA(C)al
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 La Roche-Posay
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Altos Labs
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Calico Life Sciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 BioAge Labs, Inc.
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Juvenescence Ltd.
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Life Biosciences, Inc.
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Insilico Medicine
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Genflow Biosciences plc
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 OisA-n Biotechnologies
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 NewLimit
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Aeovian Pharmaceuticals
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us